Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

20.87 +0.38 (+1.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,564,515
Open 20.84
Bid (Size) 20.90 (1)
Ask (Size) 21.03 (1)
Prev. Close 20.49
Today's Range 20.64 - 21.27
52wk Range 15.55 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence
 
Via Benzinga
Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga

Performance

YTD
+13.7%
+13.7%
1 Month
-12.5%
-12.5%
3 Month
-15.0%
-15.0%
6 Month
+10.4%
+10.4%
1 Year
+6.8%
+6.8%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’
Via Stocktwits
Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains
Via Stocktwits
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics
Via Business Wire
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
From Summit Therapeutics
Via Business Wire
Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends
Via Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock
Via Benzinga
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio?
Via Benzinga
Topics Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Via Investor's Business Daily
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
Top 3 Health Care Stocks You'll Regret Missing In Q3
Via Benzinga
Is Summit Therapeutics a Buy, Sell, or Hold Now?
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Gold Moves Higher; Robinhood Shares Jump
Via Benzinga
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Via Investor's Business Daily
Top movers in Monday's pre-market session
Via Chartmill
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Via Benzinga
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
From Summit Therapeutics
Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 20.87
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 10/02/25 04:00 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 2.03B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.